Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.032
Neutral
RSI(14)
50.959
Neutral
STOCH(KDJ)(9,3,3)
38.896
Neutral
ATR(14)
1.244
Low Volatility
CCI(14)
17.429
Neutral
Williams %R
65.625
Sell
TRIX(12,20)
0.032
Sell
StochRSI(14)
42.445
Buy
Progyny Inc
PGNY23.020USD
+0.380+1.68%
Close 08/27, 16:00（ET）Quotes delayed by 15 min
1.98BMarket Cap
37.68P/E TTM
TradingKey Stock Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Peers
TradingKey Stock Score
Currency: USD Updated：2025-08-26Key Insights
The company's fundamentals are relatively very healthy.Its valuation is considered fairly valued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.Despite an average stock market performance, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
10
analysts
Buy
Current Rating
28.714
Target Price
+24.09%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 48.33% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 78.98.
Undervalued
The company’s latest PE is 36.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.53M shares, decreasing 22.84% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 9.85M shares of this stock.
Financial Health
Currency: USD Updated：2025-08-26The company's current financial score is 8.08, which is higher than the Healthcare Services & Equipment industry's average of 7.15. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 324.04M, representing a year-over-year increase of 16.53%, while its net profit experienced a year-over-year increase of 10.88%.
Score
Financials
9.55
Related Indicators
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
9.05
Operational Efficiency
7.52
Growth Potential
7.19
Shareholder Returns
7.10
Valuation Dimension
Currency: USD Updated：2025-08-26The company’s current valuation score is 4.80, which is higher than the Healthcare Services & Equipment industry's average of 2.15. Its current P/E ratio is 36.59, which is 89.20% below the recent high of 69.22 and -3.04% above the recent low of 37.70.
Score
Valuation Dimension
P/E
P/B
P/S
P/CF
Industry Ranking 30/281
No Data
Forecast
Currency: USD Updated：2025-08-26The company’s current earnings forecast score is 7.80, which is higher than the Healthcare Services & Equipment industry's average of 7.66. The average price target for Progyny Inc is 30.00, with a high of 32.00 and a low of 23.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
10
analysts
Buy
Current Rating
28.714
Target Price
+26.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
9
Total
21
Median
19
Average
Company name
Ratings
Analysts
Progyny Inc
PGNY
10
UnitedHealth Group Inc
UNH
28
Humana Inc
HUM
27
Cigna Group
CI
26
Elevance Health Inc
ELV
24
Centene Corp
CNC
21
1
2
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Momentum
Currency: USD Updated：2025-08-26The company’s current price momentum score is 6.86, which is lower than the Healthcare Services & Equipment industry's average of 7.39. Sideways: Currently, the stock price is trading between the resistance level at 25.59 and the support level at 20.47, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
23.092
Sell
MA10
23.049
Sell
MA20
22.944
Buy
MA50
22.644
Buy
MA100
22.304
Buy
MA200
20.769
Buy
Institutional Confidence
Currency: USD Updated：2025-08-26The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Services & Equipment industry's average of 7.19. The latest institutional shareholding proportion is 107.94%, representing a quarter-over-quarter increase of 1.41%. The largest institutional shareholder is The Vanguard, holding a total of 9.85M shares, representing 11.46% of shares outstanding, with 12.72% increase in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Seidenberg (Beth C)
Kleiner, Perkins, Caufield & Byers
Thrivent Asset Management, LLC
Fidelity Management & Research Company LLC
State Street Global Advisors (US)
ArrowMark Colorado Holdings, LLC
Fred Alger Management, LLC
1
2
Risk Assessment
Currency: USD Updated：2025-08-26The company's beta value is 1.33. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.33
VaR
+4.81%
240-Day Maximum Drawdown
+44.92%
240-Day Volatility
+64.34%
Return
Best Daily Return
60 days
+13.15%
120 days
+13.15%
5 years
+38.23%
Worst Daily Return
60 days
-4.81%
120 days
-9.33%
5 years
-32.65%
Sharpe Ratio
60 days
+0.76
120 days
+0.45
5 years
+0.17
Risk Assessment
Maximum Drawdown
240 days
+44.92%
3 years
+69.26%
5 years
+79.49%
Return-to-Drawdown Ratio
240 days
-0.05
3 years
-0.20
5 years
-0.06
Skewness
240 days
-3.23
3 years
-1.80
5 years
+0.11
Volatility
Realised Volatility
240 days
+64.34%
5 years
+57.81%
Standardised True Range
240 days
+3.78%
5 years
+7.28%
Downside Risk-Adjusted Return
120 days
+67.78%
240 days
+67.78%
Maximum Daily Upside Volatility
60 days
+43.17%
Maximum Daily Downside Volatility
60 days
+26.14%
Liquidity
Average Turnover Rate
60 days
+1.25%
120 days
+1.44%
5 years
--
Turnover Deviation
20 days
-12.00%
60 days
-15.47%
120 days
-2.68%
Peers
Currency: USD Updated：2025-08-26Progyny Inc
PGNY
6.67 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Insulet Corp
PODD
7.26 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Merit Medical Systems Inc
MMSI
7.23 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Brightspring Health Services Inc
BTSG
7.19 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Tenet Healthcare Corp
THC
7.14 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
TMO
7.14 /10
Score
Financial Health
Valuation Dimension
Forecast
Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
